About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Articles

Evaluation of β-blocker Dose Optimisation Among Patients Attending Heart Failure Clinic at Sarawak Heart Centre, Malaysia

Published:

14 December 2021

Citation:

European Cardiology Review 2021;16:e71.

The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction-induced Heart Failure by Inhibiting p300-HAT Activity in Rats

Published:

14 December 2021

Citation:

European Cardiology Review 2021;16:e68.

Early Initiation of Tolvaptan is Associated with Early Discharge in Elderly Heart Failure Patients

Published:

14 December 2021

Citation:

European Cardiology Review 2021;16:e67.

Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening Assay

Published:

14 December 2021

Citation:

European Cardiology Review 2021;16:e66.